Everybody likes to paint a pretty picture, and hates to show they fud up, but all pictures are
not pretty. Key is to make more money on your winners, and not let losers get too big. I fail.
I have 14,657 shares of ALACW. Current loss $12,644. I need $1.02 to turn green.
Parent ALAC is supposed to bring SolarMax public. If you look at a ALAC chart it looks like
someone knows something. I don't think so. When there was an opportunity for shareholders to
get refunded, a vast majority did. Per an SEC filing January 5th, the deal has to be done by 3/14.
Good possibility the warrants go to zero.
I have 22,250 shares of CTXR. $15,181 in the red. Need $2.23 to break even. Jmho, I'm going to
make money before the year is out. Two drugs coming out of phase three by end of year.
Do your own dd. Biotechs always paint a pretty picture. From their last call Feb. 10th:
As of December 31, 2021, the Company had $65.4 million in cash and cash equivalents and no debt.
"We anticipate 2022 will be a year of important catalysts for Citius. The timeline for the I/ONTAK
program remains on track, with topline results anticipated in the first half of 2022, followed by
a planned BLA filing in the second half of the year. Moreover, the FDA confirmed that no pediatric
study will be required for I/ONTAK, further de-risking this asset," stated Myron Holubiak,
President and Chief Executive Officer of Citius Pharmaceuticals.
"Covid-19 continues to pose a challenge to the Mino-Lok(R) Phase 3 trial. We remain committed to
completing the trial this year and believe we are well-positioned to continue our efforts as Covid-
19 infections and hospitalizations subside, restrictions are lifted and the overall environment for
clinical trials improves. These efforts include active engagement with our existing sites, and
evaluation of additional trial sites. We continue to believe that there is a significant unmet
medical need to salvage catheters so that critically ill patients need not undergo the painful and
costly removal and replacement of a central venous line. |
